Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO
Submitted by
admin
on June 3, 2012 - 12:41pm
Source:
Yahoo/Business Wire
News Tags:
Advaxis
cervical cancer
ADXS-HPV
Headline:
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO
Do Not Allow Advertisers to Use My Personal information
